$1.74
+0.06
(+3.57%)▲
Insights on Biovie Inc
In the last 1 year, Seagen, Inc. has given 73.8% return, outperforming this stock by 143.2%
In the last 3 years, Novo Nordisk A/s has given 18.7% return, outperforming this stock by 99.7%
6.55%
Downside
Day's Volatility :9.67%
Upside
3.33%
0.0%
Downside
52 Weeks Volatility :87.9%
Upside
87.9%
Period | Biovie Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -45.1% | -1.3% | 0.0% |
6 Months | -69.95% | 1.2% | 0.0% |
1 Year | -67.75% | -5.7% | -6.5% |
3 Years | -80.97% | 17.1% | -6.5% |
Market Capitalization | 188.1M |
Book Value | $0.21 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -1.46 |
Wall Street Target Price | 11.5 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -126.35% |
Return On Equity TTM | -748.41% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -46.9M |
Diluted Eps TTM | -1.46 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.76 |
EPS Estimate Next Year | -1.44 |
EPS Estimate Current Quarter | -0.31 |
EPS Estimate Next Quarter | -0.24 |
What analysts predicted
Upside of 560.92%
Sell
Neutral
Buy
Biovie Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Biovie Inc | -58.72% | -69.95% | -67.75% | -80.97% | -83.18% |
![]() Moderna, Inc. | 10.77% | -38.07% | -54.62% | -47.66% | 329.19% |
![]() Regeneron Pharmaceuticals, Inc. | -2.11% | 8.61% | 7.86% | 65.47% | 118.58% |
![]() Novo Nordisk A/s | -0.67% | 27.21% | 58.01% | 196.12% | 339.58% |
![]() Seagen, Inc. | -0.71% | 8.98% | 75.48% | 18.69% | 248.26% |
![]() Vertex Pharmaceuticals Incorporated | -8.97% | 5.01% | 10.57% | 53.8% | 97.36% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Biovie Inc | NA | NA | NA | -1.76 | -7.48 | -1.26 | 0.0 | 0.21 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -11.52 | -0.22 | -0.07 | 0.0 | 35.32 |
![]() Regeneron Pharmaceuticals, Inc. | 22.78 | 22.78 | 9.01 | 42.5 | 0.17 | 0.09 | 0.01 | 234.47 |
![]() Novo Nordisk A/s | 43.04 | 43.04 | 2.03 | 2.62 | 0.89 | 0.22 | 0.01 | 20.77 |
![]() Seagen, Inc. | NA | NA | 18.53 | -4.16 | -0.28 | -0.13 | 0.03 | 13.52 |
![]() Vertex Pharmaceuticals Incorporated | 26.52 | 26.52 | 0.41 | 15.04 | 0.23 | 0.14 | 0.02 | 64.05 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Biovie Inc | Buy | $188.1M | -83.18% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $29.6B | 329.19% | 24.73 | -38.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $87.0B | 118.58% | 22.78 | 30.47% |
![]() Novo Nordisk A/s | Buy | $470.4B | 339.58% | 43.04 | 35.11% |
![]() Seagen, Inc. | Hold | $40.0B | 248.26% | NA | -32.61% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $91.0B | 97.36% | 26.52 | 35.94% |
Ikarian Capital, LLC
Vanguard Group Inc
Geode Capital Management, LLC
BOOTHBAY FUND MANAGEMENT, LLC
Moore Capital Management, LP
State Street Corporation
Biovie Inc’s price-to-earnings ratio stands at None
Read Morebiovie inc. (otc pink: bivi) is developing novel drug therapies for life-threatening complications of chronic liver disease. our initial target is ascites, which can occur in patients with advanced cirrhosis due to hepatitis, nash (non-alcoholic steatohepatitis), or alcoholism. ascites affects about 100,000 americans and carries an estimated 40% mortality rate within two years of being diagnosed. the company’s new drug candidate biv201 is about to enter a phase 2 clinical trial in the us. it’s based on a drug (terlipressin) not yet available in the us, but approved in about 40 countries for treating related complications of liver cirrhosis. the fda has never approved a drug to treat ascites and there is a significant unmet medical need for our novel therapy, which has orphan drug status. biovie has attracted funding from strategic investors including aspire capital, cuong do, the global strategy lead for samsung, and hari kumar, founder of adheron therapeutics which he sold to roche fo
Organization | Biovie Inc |
Employees | 18 |
CEO | Mr. Cuong Viet Do M.B.A., MBA |
Industry | Biotechnology |
Asymmetric Smart Alpha S&p 500 Etf
$1.74
+3.57%
Advisorshares Alpha Dna Equity Sentiment Etf
$1.74
+3.57%
Liberty Tripadvisor Hdg-b
$1.74
+3.57%
Tempo Automation Holdings Inc
$1.74
+3.57%
Falcon's Beyond Global Inc
$1.74
+3.57%
Jaguar Global Growth Corporation I
$1.74
+3.57%
Missfresh Ltd
$1.74
+3.57%
Shuaa Partners Acquisition Corp I
$1.74
+3.57%
Rose Hill Acquisition Corp
$1.74
+3.57%